Prospective study on comparison between the efficacy of ulipristal acetate and mifepristone in the management of fibroids in the reproductive age group
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20254293Keywords:
Fibroid, Mifepristone, Ulipristal acetateAbstract
Background: Uterine fibroids are the most common benign tumours found in women of reproductive age. Women experience symptoms affecting their quality of life, which include menorrhagia, pelvic pain, and pressure symptoms. In severe cases, fibroid causes infertility and pregnancy complications. Surgical interventions such as hysterectomy and myomectomy are effective, but invasive. Recently, selective progesterone receptor modulators (SPRMs) have emerged for the medical management, which include mifepristone and ulipristal acetate.
Methods: This was a prospective, observational clinical cohort study that enrolled 132 women, 66 in each group of ulipristal and mifepristone, conducted over a period of 18 months. Eligible participants were identified from the Outpatient Department at RIMS.
Results: After treatment, Hb levels increased to 9.9 g/dl (13.8% increase) with Ulipristal acetate and 10.4 g/dl (14.3% increase) with Mifepristone (p<0.001). The findings indicate a significant improvement in Hb levels with both treatments, with Mifepristone showing a slightly greater increase. Before treatment, both groups had a similar mean endometrial thickness of 5.8 mm (p=0.5471). After treatment, thickness increased significantly to 7.2 mm in the Ulipristal acetate group and 8.7 mm in the Mifepristone group (p=0.001).
Conclusions: Mifepristone (25 mg) may be preferable for patients with larger-sized fibroids and anemia. Ulipristal Acetate (5 mg) is beneficial for women having menorrhagia. Endometrial thickness should be regularly assessed in patients. Liver function tests (LFTs) should be performed periodically, particularly for Ulipristal Acetate users.
References
Kochar S, Suthar N, Chaudhary S, Chandad S. A prospective clinical trial to evaluate the role of very low dose mifepristone 10 mg in medical management of uterine leiomyoma in tertiary care hospital from North West India. Int J Reprod Contracept Obstet Gynecol 2020;9(4):1632-5.
Im A, Appleman LJ. Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. Expert Opin Pharmacother. 2010;11(3):481-8.
Hadi VP. To Evaluate the Safety and Efficacy of Low Dose Mifepristone in Medical Management of Uterine Leiomyoma in Karnataka Institute of Medical Sciences, Hubli - ProQuest. n.d.
Islam MS, Chen LW, Segars JH. Selective Progesterone Receptor Modulators (SPRMs) and Androgen Receptor Modulators (SARMs) as treatment for benign gynecologic diseases. Clin Obstet Gynecol. 2021;64(4):813.
Pohl O, Harvey P, McKeag S, Boley S, Gotteland J-P. Carcinogenicity and chronic rodent toxicity of the selective progesterone receptor modulator ulipristal acetate. Curr Drug Saf. 2013;8(2):77-97.
Glass Lewis M, Ekúndayò O. Cost and distribution of hysterectomy and uterine artery embolization in the United States: regional/rural/urban disparities. Med Sci. 2017;5(2):10.
Murji A, Bedaiwy M, Singh SS, Bougie O. Influence of ethnicity on clinical presentation and quality of life in women with uterine fibroids: results from a prospective observational registry. J Obstet Gynaecol Can. 2020;42(6):726-733.e1.
Lee DW, Gibson TB, Carls GS, Ozminkowski RJ, Wang S, Stewart EA. Uterine fibroid treatment patterns in a population of insured women. Fertil Steril. 2009;91(2):566-74.
Orellana M, Riggan KA, DSouza K, Stewart EA, Venable S, Balls-Berry JE, et al. Perceptions of ethnoracial factors in the management and treatment of uterine fibroids. J Racial Ethn Health Disparit. 2022;9(4):1184-91.
Millien C, Manzi A, Katz AM, Gilbert H, Smith Fawzi MC, Farmer PE, et al. Assessing burden, risk factors, and perceived impact of uterine fibroids on women’s lives in rural Haiti: implications for advancing a health equity agenda, a mixed methods study. Int J Equity Health. 2021;20(1):1.
Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, prevalence, and treatment of uterine fibroids: a survey of U.S. Women. J Womens Health. 2018;27(11):1359-67.
Henshaw CA, Goreish MH, Gornet ME, Cross CI. The Impact of Uterine Fibroids on Fertility: How the Uncertainty Widens the Gap in Reproductive outcomes in black women. Reprod Sci 2022;29(7):1967-73.
Evans J, Jones K. The role of socioeconomic status in uterine fibroid awareness and treatment: a narrative review. Ther Adv Reprod Health 2024;18:26334941241297634.
VanNoy BN, Bowleg L, Marfori C, Moawad G, Zota AR. Black women’s psychosocial experiences with seeking surgical treatment for uterine fibroids: implications for clinical practice. Womens Health Issues. 2021;31(3):263-70.
Sekula N, Jiang C, Malone A, Caldwell MT, Wise LA, Marsh EE. Racial and socioeconomic disparities in 2019 emergency department utilization for fibroids in the United States. Fertil Steril 2022;118(4):e367.
Rakshit A. A comparative prospective observational study on the use of ulipristal acetate versus mifepristone in reduction of the size of uterine leiomyoma. Asian J Med Sci. 2022;13(1):129-35.
Singh Prof (Dr) S. Efficacy and safety of mifepristone vs ulipristal acetate in medical management of fibroid- a comparative study. J Med Sci Clin Res. 2021;09(04).
Dahiya P, Bansal I, Kansal R, Beniwal A, Beniwal A. To compare the efficacy of ulipristal acetate and mifepristone in management of uterine fibroids in symptomatic patients of reproductive age group. J Contemp Medi Res. 2019;6(11):K6-9.
Downloads
Published
How to Cite
Issue
Section
